- Axsome Therapeutics to Present at Upcoming Investor Conferences
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
- Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
- Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
- Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
More ▼
Key statistics
As of last trade Axsome Therapeutics Inc (AXSM:NMQ) traded at 77.58, -21.16% below its 52-week high of 98.40, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 76.61 |
---|---|
High | 77.96 |
Low | 76.29 |
Bid | 77.47 |
Offer | 77.69 |
Previous close | 76.54 |
Average volume | 525.54k |
---|---|
Shares outstanding | 47.50m |
Free float | 38.30m |
P/E (TTM) | -- |
Market cap | 3.64bn USD |
EPS (TTM) | -6.38 USD |
Data delayed at least 15 minutes, as of May 20 2024 15:33 BST.
More ▼